Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? - Wikidata - wikimedia - TriplyDB

Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?

Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?

http://www.wikidata.org/entity/Q38295850

about

Personalized treatment of hepatitis B.HBV: Do I treat my immunotolerant patients?Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.

P2860

Q35231805-712DB579-1AC5-40DA-BD81-D06AEE775D53 Q38685592-59E99A21-DC61-4F2A-B339-E9F93338CE1B Q41042019-9EC0A407-1FEF-4301-96A5-792B9ADF514F

P2860

Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?

http://www.wikidata.org/entity/Q38295850

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?

@en

type

label

Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?

@en

prefLabel

Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?

@en

P1433

Q38295850-C34AFB0F-2344-4BDB-B568-A4179314B1A8

P1476

Q38295850-17F09DD8-0A8B-4653-B4A4-E2BE1FBBB2B0

P2093

Q38295850-4EEF1C5A-B980-40B3-825D-A84F38B349AB

P2860

Q38295850-08EC586A-2F56-4BFF-912C-1CF5AA66D2DD

Q38295850-0AFC4CF6-EE1A-41D4-8BBA-0DA0E88DE81E

Q38295850-133CCFEF-7569-473B-B248-F38C663ED51B

Q38295850-157E51B1-76F4-48AF-A67B-14C88C397A7F

Q38295850-16FDF6B8-1F6D-419A-A7D3-42E345165F1A

Q38295850-1CCF2BEB-B3FB-47FB-8D63-B3A11A17EF97

Q38295850-1E143F45-107F-4BAC-86AC-E6F19C5BF3E0

Q38295850-23A9324A-7C0D-49D9-8970-DEDDF6E1C9EB

Q38295850-247C0C8D-E1DC-49A2-8DA0-2BA2A56BDF1E

Q38295850-2BBD16D4-C0A8-4904-81DF-7CB1B64A12BE

P304

Q38295850-4FE92AE6-3A25-4FCA-9F73-C62BEED9AF15

P31

Q38295850-6D83FFF8-6CEC-4484-A166-EC48F7D28C24

P356

Q38295850-290B404B-CAA0-4132-AD9B-D8E57DAE6EFE

P478

Q38295850-1B775CFB-B72B-4BC2-B095-0345A68D1522

P50

Q38295850-F63D797C-EE34-4F01-B507-B6A45090E52D

P577

Q38295850-180F1724-4C2E-41FB-AF92-74BC4E6B53ED

P698

Q38295850-C449A795-F58C-4ED2-9BF1-26430A301B2B

P356

P1433

Liver International

P1476

Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?

@en

P2093

Jiannis Vlachogiannakos

http://www.w3.org/2001/XMLSchema#string

P2860

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Chronic hepatitis B: update 2009

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.

Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment.

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

P304

100-106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/LIV.12719

http://www.w3.org/2001/XMLSchema#string

P478

35 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

George Papatheodoridis

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25529094

http://www.w3.org/2001/XMLSchema#string